Virtue of methotrexate in ectopic pregnancy

Abstract

In recent times there is a shortfall of care about ectopic pregnancy among everyone, inciting conceded finding and potentially non -violent results. Ectopic pregnancy is a very dangerous medical disorder. This occurs when a fertilised egg implants outside of the uterus, generally in the fallopian tube. Making up 5%–10% of all pregnancy-related deaths, ectopic pregnancies are the leading cause of maternal death in the first trimester. Methotrexate is a folic acid inhibitor. It interferes with DNA synthesis and cell multiplication by inhibiting the spontaneous synthesis of purines and pyrimidines. Methotrexate will be used in the middle of six and eight weeks of pregnancy. The likelihood of a future pregnancy succeeding after using methotrexate is generally positive, according to studies. However, a few things could have an impact on these odds. As per to research, ectopic pregnancies are more common among women of reproductive age, usually between the ages of 20 and 35. Given that they are more likely to be sexually active and trying to get pregnant, women in this age range are at their most fertile. Additionally, the prevalence of sexually transmitted diseases (STIs) is higher in this age group, which can mark up the chance of an ectopic pregnancy. Factors affecting ectopic pregnancy risk include previous pelvic surgeries, infections, in vitro fertilization [IVF], endometriosis, smoking, assisted reproductive technologies, and tubal sterilization or previous pregnancies. This review of the literature attempts to shed insight on how methotrexate is currently used to treat ectopic pregnancies